Shopping Cart
Remove All
Your shopping cart is currently empty
Crotedumab (Synonyms: REGN1193, REGN 1193, Anti-GCGR Reference Antibody)
Catalog No. T76862 Copy Product Info
🥰Excellent
Crotedumab (REGN1193) is a humanized antibody targeting GCGR, which reduces fasting blood glucose and improves glucose tolerance, used in diabetes research.
Crotedumab
Copy Product Info🥰Excellent
Catalog No. T76862
Synonyms REGN1193, REGN 1193, Anti-GCGR Reference Antibody
Crotedumab (REGN1193) is a humanized antibody targeting GCGR, which reduces fasting blood glucose and improves glucose tolerance, used in diabetes research.
Crotedumab
Cas No. 1452387-69-7
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $197 | In Stock | In Stock | |
| 5 mg | $516 | In Stock | In Stock | |
| 10 mg | $828 | - | In Stock | |
| 25 mg | $1,230 | - | In Stock | |
| 50 mg | $1,650 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:96.61% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Crotedumab (REGN1193) is a humanized antibody targeting GCGR, which reduces fasting blood glucose and improves glucose tolerance, used in diabetes research. |
| Targets&IC50 | GCGR:0.1 nM (Kd) |
| In vitro | Crotedumab inhibits glucagon-induced signaling in transfected human, monkey, mouse, and rat HEK293 cells via GCGR with IC50 values of 0.65, 3.2, 0.94, and 1.0 nM, respectively.[1] |
| In vivo | Administration of Crotedumab (a single subcutaneous injection) to diabetic OB/OB and diet-induced obese mice reduced blood sugar to levels observed in GCGR deficient mice. In diet-induced obese mice, Crotedumab reduced food intake, adipose tissue mass, and body weight. A single administration of Crotedumab in diabetic cynomophagus monkeys normalized fasting blood sugar and glucose tolerance, and increased circulating levels of glucagon and amino acids. [1] |
| Synonyms | REGN1193, REGN 1193, Anti-GCGR Reference Antibody |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | GCGR/GLR |
| Molecular Weight | 146.82 kDa |
| Cas No. | 1452387-69-7 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
Preview
Related Tags: buy Crotedumab | purchase Crotedumab | Crotedumab cost | order Crotedumab | Crotedumab in vivo | Crotedumab in vitro | Crotedumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.